Glyde Bio is an immune-oncology startup that are exploiting the aberrantly glycosylated cancer proteome as a new and rich source of tumor neoantigens. Their aim is to mine the cancer glycome as a rich source of neoantigens for cancer immune-therapy. Glyde’s platform technologies of conjugate vaccines, applied immunology, glycobiology, and glycol-proteomics are driving the development of first generation clinical candidates and the discovery of new tumor-specific glycans for next generations cancer therapies. Since starting at Nest.Bio Labs, they have raised about $10M in fundraising.

We provide shared lab and office space for life science startups. Learn more about our shared lab space in Cambridge and ventures

Contact Us 

(617) 245-8548

hello@nest.bio

325 Vassar St., Suite 2A

Cambridge, MA 02139

Review us on Google!

Quick Links

Our Services

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram